ArticleFrontiers in medicine2026
Rechallenge of ruxolitinib after momelotinib-related toxicity in a 74-yo woman with secondary myelofibrosis: a case report.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the era of new JAK inhibitors (JAKi), combination therapy, and other targeted therapies, it seems especially important to optimize the treatment options. The rechallenge of a JAKi becomes one of the possibilities, already reported in the literature, the better documented, between ruxolitinib and fedratinib. To date, no case of rechallenge between ruxolitinib and momelotinib (MMB) has been reported. Short report: We present a case of secondary-to-ET myelofibrosis in a 74-year-old female initially treated by high-dose ruxolitinib, switched to momelotinib because of transfusion-dependent anemia, and who developed significant peripheral neuropathy and arthralgias during treatment with momelotinib, unsuccessfully managed by dose reductions, and subsequently re-switched to low-dose ruxolitinib due to the improvement of anemia after MMB and the objective of maintaining symptom control. Conclusion: This case highlights the possibility of revisiting JAKi after momelotinib, depending on therapeutic objectives and to manage adverse effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.